NOVOZYMES A/S SPONS.ADR 1 Cash Flow-to-Debt Ratio
NOVOZYMES A/S SPONS.ADR 1 cash flow-to-debt ratio. NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of €167.10 Million could theoretically repay 0% of its total liabilities (€5.60 Billion) in one year. Check NZM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Cash flow-to-debt ratio of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. Historical debt coverage capacity for NOVOZYMES A/S SPONS.ADR 1 across 5 annual periods. Check how high is NOVOZYMES A/S SPONS.ADR 1's earnings quality to evaluate the quality of earnings relative to operating cash generation.
NOVOZYMES A/S SPONS.ADR 1 Cash Flow-to-Debt Ratio by Year (2021–2025)
NOVOZYMES A/S SPONS.ADR 1 cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for NOVOZYMES A/S SPONS.ADR 1. For the full cash flow conversion analysis, see NOVOZYMES A/S SPONS.ADR 1 operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.22x | €1.22 Billion | €5.49 Billion | ▼ -12.4% |
| 2024 | 0.25x | €1.02 Billion | €4.02 Billion | ▼ -14.2% |
| 2023 | 0.30x | €557.10 Million | €1.88 Billion | ▲ +1.5% |
| 2022 | 0.29x | €537.65 Million | €1.85 Billion | ▼ -9.9% |
| 2021 | 0.32x | €546.17 Million | €1.69 Billion | — |